DE69921348T2 - Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung - Google Patents

Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung Download PDF

Info

Publication number
DE69921348T2
DE69921348T2 DE69921348T DE69921348T DE69921348T2 DE 69921348 T2 DE69921348 T2 DE 69921348T2 DE 69921348 T DE69921348 T DE 69921348T DE 69921348 T DE69921348 T DE 69921348T DE 69921348 T2 DE69921348 T2 DE 69921348T2
Authority
DE
Germany
Prior art keywords
angiogenic
fgf
unit dose
rfgf
active fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69921348T
Other languages
German (de)
English (en)
Other versions
DE69921348D1 (de
Inventor
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69921348D1 publication Critical patent/DE69921348D1/de
Application granted granted Critical
Publication of DE69921348T2 publication Critical patent/DE69921348T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69921348T 1998-09-03 1999-08-27 Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung Expired - Lifetime DE69921348T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14574398P 1998-09-03 1998-09-03
US145743P 1998-09-03
US10410398P 1998-10-13 1998-10-13
US10410298P 1998-10-13 1998-10-13
US104103P 1998-10-13
US104102P 1998-10-13
PCT/US1999/019770 WO2000013701A2 (en) 1998-09-03 1999-08-27 Angiogenically effective unit dose of fgf-2 and method of use

Publications (2)

Publication Number Publication Date
DE69921348D1 DE69921348D1 (de) 2004-11-25
DE69921348T2 true DE69921348T2 (de) 2006-02-09

Family

ID=27379656

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69921348T Expired - Lifetime DE69921348T2 (de) 1998-09-03 1999-08-27 Fgf-2 angiogenische wirksame einheitdosis und ihrer verwendung
DE69941034T Expired - Lifetime DE69941034D1 (de) 1998-09-03 1999-08-27 Fgf-2 angiogenische wirksame Einheitdosis und verfahren zu ihrer Verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69941034T Expired - Lifetime DE69941034D1 (de) 1998-09-03 1999-08-27 Fgf-2 angiogenische wirksame Einheitdosis und verfahren zu ihrer Verwendung

Country Status (7)

Country Link
EP (2) EP2123292B1 (https=)
JP (2) JP5329729B2 (https=)
AT (2) ATE279937T1 (https=)
AU (1) AU6022399A (https=)
DE (2) DE69921348T2 (https=)
ES (2) ES2233101T3 (https=)
WO (1) WO2000013701A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2002527401A (ja) 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
JP5704780B2 (ja) * 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
US20020032153A1 (en) * 2000-03-10 2002-03-14 Whitehouse Martha Jo Methods and compositions for the treatment and prevention of erectile dysfunction
EP1894570A3 (en) * 2000-06-22 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Methods and compositions for the treatment of peripheral artery disease
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR101413844B1 (ko) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
WO2018200040A1 (en) * 2017-04-26 2018-11-01 University Of Cincinnati Compositions of fibroblast growth factor ligands and methods of treating patients unergoing ischemia-reperfusion therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956455A (en) 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
ATE105868T1 (de) * 1985-09-12 1994-06-15 Scios Nova Inc Rekombinanter fibroblast-wachstumsfaktor.
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins

Also Published As

Publication number Publication date
JP2002524420A (ja) 2002-08-06
DE69941034D1 (de) 2009-08-06
JP5329729B2 (ja) 2013-10-30
AU6022399A (en) 2000-03-27
ES2233101T3 (es) 2005-06-01
EP2123292A1 (en) 2009-11-25
EP2123292B1 (en) 2016-05-04
DE69921348D1 (de) 2004-11-25
ATE279937T1 (de) 2004-11-15
WO2000013701A3 (en) 2000-08-03
WO2000013701A2 (en) 2000-03-16
JP2010163457A (ja) 2010-07-29
EP1121142A2 (en) 2001-08-08
EP1121142B1 (en) 2004-10-20
ATE434440T1 (de) 2009-07-15
WO2000013701A9 (en) 2000-10-05
HK1075409A1 (en) 2005-12-16
ES2327839T3 (es) 2009-11-04

Similar Documents

Publication Publication Date Title
DE60132343T2 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
US7858584B2 (en) Angiogenically effective unit dose of FGF and method of administering
JP2020117546A (ja) 脈管形成因子の用量および心筋血流を改善するための投与方法
US6440934B1 (en) Angiogenically effective unit dose of FGF-2 and method of use
JP2003519097A5 (https=)
US20140349932A1 (en) Angiogenically effective unit dose of fgf-2 and method of use
JP2010053145A (ja) 血管形成的に有効なｆｇｆ−２の単位用量および使用方法
JP2010163457A (ja) 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
US9149507B2 (en) Method of treating coronary artery disease by administering FGF-9
EP1525888B1 (en) Angiogenically effective unit dose of FGF-2 and method of use
HK1075409B (en) Angiogenically effective unit dose of fgf-2 and method of use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US